CHEMO-IMMUNE THERAPY

A translational approach evaluating novel strategies using chemotherapy to enhance immune-mediated anti-tumor activity

 Coordinatore KAROLINSKA INSTITUTET 

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Ms.
Nome: Kristina
Cognome: Geiger
Email: send email
Telefono: +46 8 51775878
Fax: +46 8 51770690

 Nazionalità Coordinatore Sweden [SE]
 Totale costo 100˙000 €
 EC contributo 100˙000 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2009-RG
 Funding Scheme MC-IRG
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-11-01   -   2013-10-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Ms.
Nome: Kristina
Cognome: Geiger
Email: send email
Telefono: +46 8 51775878
Fax: +46 8 51770690

SE (STOCKHOLM) coordinator 100˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

effect    doxorubicin    tests    outcomes    cancerous    treatment    mice    cells    therapy    killer    ability    successful    modalities    combination    patients    nk    tumor    agents    natural    sensitivity    vitro    responses    combined    anti    cancer    pre    therapies    allogeneic    vivo    tumour    cell    clinical    immune    ap    chemotherapy   

 Obiettivo del progetto (Objective)

'A wealth of successful pre-clinical immunotherapy-based treatment protocols against cancer have been documented, yet only a limited number of clinical trials have proven to be successful. A common consensus among clinical and bench-side researchers is that a combination of several treatment modalities should be used to achieve complete tumor regression. In recent years, evidence that chemotherapy agents can be used to enhance immune-based therapies has emerged. The specific aims described below are designed to evaluate novel treatment modalities against cancer using chemotherapy agents that have the ability to sensitize tumors to both innate and adaptive anti-tumor immune responses. 1. Examine the effect of different chemotherapy agents in their ability to modify tumor susceptibility to autologous and allogeneic natural killer (NK) and T cell -mediated apoptosis in vitro. 2. In vivo confirmation and evaluation of selected agents in murine syngeneic and allogeneic hematopoietic stem cell transplantation (HCT) tumor models. The results of these studies will lay a foundation for NK cell-based and T cell-based therapies which could lead to more effective treatments for cancer patients. In addition to defining mechanisms how the various chemotherapy agents may influence NK or T cell anti-tumor responses, several subsidiary projects derived from this research will most likely develop.'

Introduzione (Teaser)

The immune system plays a key role when it comes to fighting infections or preventing diseases. This is particularly important in the fight against cancer.

Descrizione progetto (Article)

Presence of immune cells such as T cells and natural killer (NK) cells in tumour sites has been linked to favourable outcomes in cancer patients. Research has also shown that chemotherapy agents increase the sensitivity of cancerous cells to immune cells to facilitate death of cancer cells.

The EU-funded CHEMO-IMMUNE THERAPY project evaluated the ability of different chemotherapy agents to sensitise tumour cells to combined therapy with T and NK cells.

To begin with, scientists isolated NK and T cells from melanoma patients and tested for anti-cancer activity on different cancer cell lines in vitro. Over a dozen chemotherapy agents were screened to assess their tumour-sensitising ability to immune cells. Out of these, anthracyclin, doxorubicin and the proteasome inhibitor b-AP15 proved to be consistently effective.

Besides in vitro tests, in vivo tests on mice with cancer were also performed to assess the effect of pre-treatment with doxorubicin or b-AP15. Both agents successfully increased sensitivity of cancer cells to immune cells without affecting normal cells. Combined infusion of NK and T cells in cancerous mice that were pre-treated with chemotherapy showed a significant increase in survival and reduced tumour progression.

Successful clinical trial outcomes may improve the prognosis of most cancer patients through such combination therapies.

Altri progetti dello stesso programma (FP7-PEOPLE)

S.O.F.T. (2014)

"Swimmers: one, few, thousands"

Read More  

REGOPOC (2012)

Regulation of Plant Potassium Channels

Read More  

OCEANQUANT (2014)

Quantification of Past Ocean Circulation

Read More